BiomX (NYSEAMERICAN:PHGE) Stock Set to Reverse Split on Wednesday, September 9th

Shares of BiomX Inc. (NYSEAMERICAN:PHGE) are scheduled to reverse split on the morning of Wednesday, September 9th. The 1-10 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Tuesday, September 8th.

BiomX Price Performance

Shares of PHGE stock opened at $0.14 on Tuesday. The company has a market capitalization of $3.66 million, a P/E ratio of -0.04 and a beta of 1.35. The company’s 50-day simple moving average is $0.22 and its two-hundred day simple moving average is $1.91. BiomX has a one year low of $0.12 and a one year high of $12.29. The company has a debt-to-equity ratio of 0.02, a current ratio of 0.24 and a quick ratio of 0.24.

BiomX (NYSEAMERICAN:PHGE) last issued its earnings results on Wednesday, August 19th. The company reported ($0.37) EPS for the quarter. The firm had revenue of $0.33 million for the quarter. As a group, equities analysts anticipate that BiomX will post -5.85 EPS for the current year.

Institutional Investors Weigh In On BiomX

An institutional investor recently bought a new position in BiomX stock. Alyeska Investment Group L.P. bought a new position in BiomX Inc. (NYSEAMERICAN:PHGE) in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor bought 1,590,738 shares of the company’s stock, valued at approximately $835,000. Alyeska Investment Group L.P. owned 5.99% of BiomX at the end of the most recent quarter. 40.57% of the stock is owned by hedge funds and other institutional investors.

About BiomX

BiomX Inc is a clinical-stage biotechnology company that specializes in developing precision bacteriophage therapies to target pathogenic bacteria in the human microbiome. By harnessing the natural ability of bacteriophages to selectively infect and lyse harmful bacterial strains, BiomX aims to restore microbial balance without disrupting beneficial commensal organisms. The company’s platform integrates phage discovery, formulation and genetic engineering to create tailored phage cocktails for a range of microbiome-associated diseases.

The company’s pipeline includes lead clinical candidates for gastrointestinal disorders such as pouchitis and ulcerative colitis, as well as programs addressing dermatological indications including acne and atopic dermatitis.